We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
- Authors
Galipeau, Patricia C; Li, Xiaohong; Blount, Patricia L; Maley, Carlo C; Sanchez, Carissa A; Odze, Robert D; Ayub, Kamran; Rabinovitch, Peter S; Vaughan, Thomas L; Reid, Brian J
- Abstract
Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may modulate progression. We aimed to evaluate somatic genetic abnormalities with NSAIDs as predictors of EA in a prospective cohort study of patients with BE.
- Publication
PLoS medicine, 2007, Vol 4, Issue 2, pe67
- ISSN
1549-1676
- Publication type
Journal Article
- DOI
10.1371/journal.pmed.0040067